Day One Skyrockets On Servier's $2.5 Billion Buyout. Could A 'White Knight' Emerge?

Core Viewpoint - Servier will acquire Day One Biopharmaceuticals for approximately $2.5 billion, enhancing its cancer treatment pipeline [1] Group 1: Acquisition Details - The acquisition price is set at $21.50 per share, representing a 68% premium over Day One's closing price prior to the announcement [1] - The deal includes Day One's Ojemda, the only drug in its class for treating low-grade glioma in children aged six months and older [1] - The transaction is expected to close in the second quarter of the year [1] Group 2: Strategic Implications - Olivier Laureau, Servier's president, emphasized that the acquisition strengthens Servier's position as a global leader in rare oncology [1] - The acquisition aligns with Servier's long-term commitment to invest in science addressing significant unmet medical needs [1] - The deal is part of Servier's 2030 ambition to accelerate innovation for patients with rare cancers [1] Group 3: Market Reaction - Following the announcement, Day One's stock surged nearly 66% after trading resumed [1] - Day One's shares were trading around $21.19 in premarket trades after the news [1] - The stock's relative strength line reached a new high prior to the acquisition announcement [1]